长春胺

长春胺
临床资料
商品名（英语：Drug nomenclature）	Oxybral SR、奥勃兰（Oxybrain）
AHFS/Drugs.com	国际药品名称
给药途径	Oral
ATC码	C04AX07 (WHO) ;
法律规范状态
法律规范	澳：限医生处方（S4）; 中：处方药 ;
识别信息
	IUPAC命名法 (3α,14β,16α)-14,15-Dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; or; Methyl (15R,17S,19R)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18)-tetraene-17-carboxylate; ;
CAS号	1617-90-9
PubChem CID	15376;
IUPHAR/BPS	349;
DrugBank	DB13374 ;
ChemSpider	14635 ;
UNII	996XVD0JHT;
KEGG	D08677 ;
ChEMBL	ChEMBL1165342 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID9040134 ;
ECHA InfoCard	100.015.070
化学信息
化学式	C21H26N2O3
摩尔质量	354.45 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES O=C(OC)[C@]3(O)n1c4c(c2ccccc12)CCN5CCC[C@](C3)(CC)[C@@H]45;
	InChI InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1 ; Key:RXPRRQLKFXBCSJ-GIVPXCGWSA-N ;

长春胺（英语：Vincamine），商品名奥勃兰（英语：Oxybrain）^[2]等，是一种单萜吲哚生物碱，存在于小蔓长春花（学名：Vinca minor）的叶中，约占其吲哚生物碱重量的25-65%。长春胺也可以从相关生物碱中合成^[3]。

用途

长春胺在欧洲作为处方药出售，用于治疗原发性退行性和血管性痴呆。在中华人民共和国，长春胺也是一种处方药，适应症包括治疗衰老期心理行为障碍、急性脑血管病及脑外伤后综合征、缺血性视网膜疾病、耳蜗前庭疾病^[2]。在美国，当标明可供成人使用六个月或更短时间时，允许将其作为膳食补充剂出售^[4]。长春胺最常见的剂型是缓释（英语：Modified-release dosage）片剂。

化学

合成

水甘草碱可用于长春胺的半合成^[5]。

衍生物

长春西汀是长春胺的衍生物，用于治疗脑血管疾病和作为膳食补充剂^[6]。长春胺衍生物也被研究作为抗成瘾剂^[7]和抗糖尿病剂^[8]。

研究

长春胺可能具有益智作用^[5]。它已被研究作为新型抗癌药物^[9]。

美国国家毒物计划记录了对长期使用长春胺的担忧^[10]。2018年，中国国家药品监督管理局根据药品不良反应评估结果，要求修订长春胺缓释胶囊说明书^[11]。

参考来源

^ STANDARD FOR THE UNIFORM SCHEDULING OF MEDICINES AND POISONS. Federal Register of Legislation. 2020-10 [2021-08-15]. （原始内容存档于2021-01-25）.
^ ^2.0 ^2.1 长春胺缓释胶囊. 丁香园·用药助手. [2025-03-14].
^ Indole Alkaloids. Ullmann's Encyclopedia of Industrial Chemistry Fifth. Wiley-VCH: 393. 1985. ISBN 3-527-20100-9.
^ Summary of Data for Chemical Selection: Vincamine (PDF). National Toxicology Program. U.S. Department of Health and Human Services.
^ ^5.0 ^5.1 Leeuwenberg AJ. Voacanga, (Apocynaceae), a review of taxonomy, phytochemistry, ethnobotany and pharmacology. Agricultural University Wageningen Papers. 1985, 85 (3). ISSN 0169-345X.
^ Vinpocetine in Dietary Supplements. FDA. 2019-06-03.
^ Norwood VM, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, Ratnayake R, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW. Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. Journal of Medicinal Chemistry. May 2020, 63 (10): 5119–5138. PMC 7324933 . PMID 31913038. doi:10.1021/acs.jmedchem.9b01924.
^ Wang J, Lv X, Xu J, Liu X, Du T, Sun G, Chen J, Shen X, Wang J, Hu L. Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry. February 2020, 188: 111976. PMID 31918073. S2CID 210133217. doi:10.1016/j.ejmech.2019.111976.
^ Al-Rashed S, Baker A, Ahmad SS, Syed A, Bahkali AH, Elgorban AM, Khan MS. Vincamine, a safe natural alkaloid, represents a novel anticancer agent. Bioorganic Chemistry. February 2021, 107: 104626. PMID 33450545. S2CID 231624167. doi:10.1016/j.bioorg.2021.104626.
^ Vincamine Dietary Supplements 1617-90-9 - National Toxicology Program (PDF). National Institute of Environmental Health Sciences. [4 December 2023].
^ 国家药品监督管理局关于修订长春胺缓释胶囊说明书的公告（2018年第9号）. 国家药品监督管理局. 2018-04-27 [2025-03-14].

参见

外部链接

Vincamine MSDS (PDF). [2012-01-30]. （原始内容 (PDF)存档于2015-06-08）.
Chemical Selection Working Group. Vincamine - 1617-90-9 (PDF). Summary of Data for Chemical Selection. NIH - United States National Institutes of Health. [2007-04-23]. （原始内容存档 (PDF)于2011-10-21）.

[1] STANDARD FOR THE UNIFORM SCHEDULING OF MEDICINES AND POISONS. Federal Register of Legislation. 2020-10 [2021-08-15]. （原始内容存档于2021-01-25）.

[dxy-2] 2.0 ^2.1 长春胺缓释胶囊. 丁香园·用药助手. [2025-03-14].

[3] Indole Alkaloids. Ullmann's Encyclopedia of Industrial Chemistry Fifth. Wiley-VCH: 393. 1985. ISBN 3-527-20100-9.

[4] Summary of Data for Chemical Selection: Vincamine (PDF). National Toxicology Program. U.S. Department of Health and Human Services.

[Leeuwenberg_1985-5] 5.0 ^5.1 Leeuwenberg AJ. Voacanga, (Apocynaceae), a review of taxonomy, phytochemistry, ethnobotany and pharmacology. Agricultural University Wageningen Papers. 1985, 85 (3). ISSN 0169-345X.

[6] Vinpocetine in Dietary Supplements. FDA. 2019-06-03.

[pmid31913038-7] Norwood VM, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, Ratnayake R, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW. Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. Journal of Medicinal Chemistry. May 2020, 63 (10): 5119–5138. PMC 7324933 . PMID 31913038. doi:10.1021/acs.jmedchem.9b01924.

[pmid31918073-8] Wang J, Lv X, Xu J, Liu X, Du T, Sun G, Chen J, Shen X, Wang J, Hu L. Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry. February 2020, 188: 111976. PMID 31918073. S2CID 210133217. doi:10.1016/j.ejmech.2019.111976.

[pmid33450545-9] Al-Rashed S, Baker A, Ahmad SS, Syed A, Bahkali AH, Elgorban AM, Khan MS. Vincamine, a safe natural alkaloid, represents a novel anticancer agent. Bioorganic Chemistry. February 2021, 107: 104626. PMID 33450545. S2CID 231624167. doi:10.1016/j.bioorg.2021.104626.

[10] Vincamine Dietary Supplements 1617-90-9 - National Toxicology Program (PDF). National Institute of Environmental Health Sciences. [4 December 2023].

[11] 国家药品监督管理局关于修订长春胺缓释胶囊说明书的公告（2018年第9号）. 国家药品监督管理局. 2018-04-27 [2025-03-14].

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]